Corifollitropin alfa
Treatment for: Female Infertility
Merck Receives Complete Response Letter from the U.S. FDA for New Drug Application for Corifollitropin Alfa
WHITEHOUSE STATION, N.J.-- July 29, 2014 (BUSINESS WIRE)-- Merck received a Complete Response Letter from the U.S. FDA for its New Drug Application for corifollitropin alfa, a sustained follicle stimulant for controlled ovarian stimulation in women participating in assisted reproductive technologies. Merck is evaluating the information provided in the Complete Response Letter. Corifollitropin alfa is marketed as ELONVA in more than 75 countries.
Posted: July 2014
Related articles
- Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment - September 9, 2013
Corifollitropin alfa FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
